Tigulixostat

替古索司他

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameTigulixostat
Drug Alias NameLC-350189IBI-350LR-19074IBI-128
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionXanthine dehydrogenase inhibitors
TargetsXanthine dehydrogenase
Therapy Area/IndicationsHyperuricemiaMetabolic DiseasesHeart Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLg Chemical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics Technology LtdLg Chemical LtdInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsHyperuricemiaMetabolic DiseasesHeart Diseases +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A